The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an “undruggable” target due to the lack of deep binding pockets for specific small-molecule inhibitors. A better understanding of the mechanisms that drive KRAS transfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Salgia, Ravi, Pharaon, Rebecca, Mambetsariev, Isa, Nam, Arin, Sattler, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817862/
https://www.ncbi.nlm.nih.gov/pubmed/33521700
http://dx.doi.org/10.1016/j.xcrm.2020.100186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817862/
https://www.ncbi.nlm.nih.gov/pubmed/33521700
http://dx.doi.org/10.1016/j.xcrm.2020.100186

Ejemplares similares